Zhejiang Jolly Pharmaceutical (300181.SZ): The Bai Ling tablets are planned to be selected for the centralized procurement of national Chinese patent medicine procurement alliance.

Zhejiang Jolly Pharmaceutical (300181.SZ) announced that recently, the company and its controlling subsidiary, Qinghai Zhufeng Dongchong Xiacao Pharmaceuticals Co., Ltd. ("Zhufeng Pharmaceuticals"), participated in the national Chinese patent medicine procurement alliance centralized procurement. According to the "Notice of Intended Selection Results of National Chinese Patent Medicine Procurement Alliance Centralized Quantity Procurement" released by the Hubei Medical Insurance Service Platform on December 30, 2024, Bairing Pills were selected for this centralized quantity procurement. The selected products Bairing Pills and Bairing Capsules are both listed in the national medical insurance and essential medicine directory. The sales revenue of Bairing Pills in 2023 was 202 million yuan, accounting for 10.39% of the company's total operating income in 2023. Not being selected in the provincial inter-provincial alliance centralized quantity procurement for Chinese patent medicine in December 2021 had a significant impact on its sales in the Hubei alliance region. This intended selection is beneficial for restoring and further increasing market share in the alliance region.